The closing price of Regenxbio Inc (NASDAQ: RGNX) was $21.98 for the day, down -3.81% from the previous closing price of $22.85. In other words, the price has decreased by -$0.87 from its previous closing price. On the day, 1350053 shares were traded.
Ratios:
Our analysis of RGNX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.57 and its Current Ratio is at 2.57. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 11, 2024, initiated with a Buy rating and assigned the stock a target price of $36.
On March 08, 2024, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $20 to $35.
Leerink Partners Upgraded its Market Perform to Outperform on March 06, 2024, while the target price for the stock was maintained at $37.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 05 ’24 when PAKOLA STEVE sold 12,878 shares for $28.36 per share. The transaction valued at 365,220 led to the insider holds 107,192 shares of the business.
Mills Kenneth T. sold 15,000 shares of RGNX for $251,349 on Feb 14 ’24. The President and CEO now owns 408,035 shares after completing the transaction at $16.76 per share. On Jan 16 ’24, another insider, Mills Kenneth T., who serves as the President and CEO of the company, sold 45,000 shares for $15.18 each. As a result, the insider received 682,992 and left with 408,035 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 1.08B and an Enterprise Value of 890.89M. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.82 while its Price-to-Book (P/B) ratio in mrq is 3.11. Its current Enterprise Value per Revenue stands at 9.87 whereas that against EBITDA is -3.72.
Stock Price History:
Over the past 52 weeks, RGNX has reached a high of $28.80, while it has fallen to a 52-week low of $11.83. The 50-Day Moving Average of the stock is 16.78, while the 200-Day Moving Average is calculated to be 17.79.
Shares Statistics:
RGNX traded an average of 790.12K shares per day over the past three months and 1.44M shares per day over the past ten days. A total of 44.05M shares are outstanding, with a floating share count of 39.84M. Insiders hold about 10.34% of the company’s shares, while institutions hold 87.27% stake in the company. Shares short for RGNX as of Feb 29, 2024 were 3.83M with a Short Ratio of 4.85, compared to 4.15M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.62% and a Short% of Float of 11.12%.
Earnings Estimates
The firm’s stock currently is rated by 10 analysts. On average, analysts expect EPS of -$1.28 for the current quarter, with a high estimate of -$1.11 and a low estimate of -$1.5, while EPS last year was -$1.53. The consensus estimate for the next quarter is -$1.24, with high estimates of -$1.06 and low estimates of -$1.47.
Analysts are recommending an EPS of between -$1.41 and -$5.7 for the fiscal current year, implying an average EPS of -$4.57. EPS for the following year is -$2.24, with 11 analysts recommending between $1.45 and -$5.15.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $34.7M to a low estimate of $16.69M. As of the current estimate, Regenxbio Inc’s year-ago sales were $19.14M, an estimated increase of 22.90% from the year-ago figure.
A total of 12 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $284.76M, while the lowest revenue estimate was $80M, resulting in an average revenue estimate of $133.61M. In the same quarter a year ago, actual revenue was $90.24M, up 48.10% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $248.76M in the next fiscal year. The high estimate is $414M and the low estimate is $117.61M. The average revenue growth estimate for next year is up 86.20% from the average revenue estimate for this year.
